Literature DB >> 34130291

Calcineurin Inhibitor Toxicity in Solid Organ Transplantation.

Andrea Karolin1, Vera Genitsch2, Daniel Sidler1.   

Abstract

Calcineurin inhibitors (CNIs) have a substantial role in maintaining immunosuppression after solid organ transplantation (SOT). These drugs have a narrow therapeutic window, and individual doses and drug treatment monitoring are necessary. Still, a substantial proportion of patients suffer from short- or long-term calcineurin inhibitor toxicity (CNT), including kidney function impairment, hypertension, neurotoxicity, and metabolic disturbances. The authors discuss pathophysiology, clinical presentation, and histological features of CNT, with focus on renal manifestations. Furthermore, we elucidate recent and ongoing attempts to reduce the burden of CNT in SOT including CNI-sparing and CNI-free regimens.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Arteriohyalinosis; Calcineurin inhibitors; Cyclosporine A; Fibrosis; Kidney disease

Year:  2021        PMID: 34130291     DOI: 10.1159/000515933

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  6 in total

1.  Recent advances in immunotherapies for lupus nephritis.

Authors:  Machi Kaneko; Shaun W Jackson
Journal:  Pediatr Nephrol       Date:  2022-07-01       Impact factor: 3.714

2.  Drug-related problems identified during pharmaceutical care interventions in an intensive care unit at a tertiary university hospital.

Authors:  Vichapat Tharanon; Krongtong Putthipokin; Phantipa Sakthong
Journal:  SAGE Open Med       Date:  2022-04-19

Review 3.  Solid organ transplantations and COVID-19 disease.

Authors:  Emine Aylin Yılmaz; Öner Özdemir
Journal:  World J Transplant       Date:  2021-12-18

4.  Nephrotoxicity of Calcineurin Inhibitors in Kidney Epithelial Cells is Independent of NFAT Signaling.

Authors:  Andrea Karolin; Geneviève Escher; Stefan Rudloff; Daniel Sidler
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

5.  First Steps toward Personalized Therapies for ABCA3 Deficiency.

Authors:  Jennifer A Wambach; Lawrence M Nogee; F Sessions Cole
Journal:  Am J Respir Cell Mol Biol       Date:  2022-04       Impact factor: 7.748

6.  Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial.

Authors:  Zhaohui Zheng; Haitao Zhang; Xiaomei Peng; Chun Zhang; Changying Xing; Gang Xu; Ping Fu; Zhaohui Ni; Jianghua Chen; Zhonggao Xu; Ming-Hui Zhao; Shaomei Li; Xiangyang Huang; Lining Miao; Xiaonong Chen; Bicheng Liu; Yongcheng He; Jing Li; Lijun Liu; Haishan Kadeerbai; Zhangsuo Liu; Zhihong Liu
Journal:  JAMA Netw Open       Date:  2022-03-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.